NPPA Bars Pricing of Loose Drugs Above Pro-Rata MRP Under DPCO, Parliament Informed

Written By :  Parthika Patel
Published On 2025-12-21 07:00 GMT   |   Update On 2025-12-21 07:01 GMT
Advertisement

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) strictly monitors drug prices under the Drugs (Prices Control) Order, 2013 (DPCO, 2013) to prevent exploitation of consumers through overpricing, including the sale of loose or unpackaged medicines at rates higher than the prescribed per-unit Maximum Retail Price (MRP), the Parliament was informed.

The clarification came in response to questions raised during a recent Lok Sabha session on alleged consumer exploitation by pharmacies and medical stores in Maharashtra, where concerns were raised about medicines being sold in loose form at inflated prices.

Advertisement

Replying to the queries, the Minister of State for Chemicals and Fertilizers, Anupriya Patel, stated that under DPCO, 2013, every manufacturer is mandatorily required to print the MRP on the label of the container of each drug formulation. She further clarified that no dealer is permitted to sell any loose quantity of a formulation at a price exceeding the pro-rata MRP calculated from the printed price on the original strip or bottle.

The Government explained that NPPA continuously monitors drug prices and takes action against companies found overcharging consumers. This surveillance is carried out through multiple mechanisms, including inputs from Price Monitoring and Resource Units (PMRUs) established in States, State Drugs Controllers (including those in Maharashtra), samples purchased from the open market, market database reports, and complaints received through grievance redressal channels.

Addressing concerns specific to Maharashtra, the Minister informed the House that NPPA has not received any complaint regarding the sale of loose or unpackaged medicines at prices significantly higher than their per-unit MRP from Maharashtra or any other source to date.

The Government reiterated that the existing regulatory framework under DPCO, 2013 is adequate to curb such practices and ensure that consumers are not charged more than the legally permissible MRP for medicines, irrespective of whether they are sold in full packs or in loose form.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News